Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

How Bad Will The Partial Hold On Sovaprevir Be For Achillion?

Achillion (NASDAQ:ACHN) investors got a huge piece of bad news on Monday evening, when this biotech virology specialist announced that its lead protease inhibitor for hepatitis C (HCV), sovaprevir, has been placed on clinical hold by the FDA after troubling safety data. With the stock down sharply in after-hours trading, this is clearly a major near-term problem for the company and the stock, and it definitely raises troubling questions about the safety profile of this drug.

While I do not believe this development devastates the long-term potential of the drug in HCV treatment, it most likely freezes any possibility of an acquisition and it is almost certainly going to appear as an issue if/when the company files for...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details